Clinical trials: Fibromyalgia, Primary
- Condition Fibromyalgia, Primary
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Fibromyalgia
Adolescent Fibromyalgia Study
This study will compare pregabalin with placebo over a 15 week period in adolescents with fibromyalgia aged 12-17 years to evaluate the safety and efficacy of pregabalin.
- Trial name
- NCT01020474
- Testing
- pregabalin (Lyrica)
- Where
- 36 sites in United States, Czechia and 2 more
- Volunteers
- 107 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary Fibromyalgia
12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients
This was an open-label, extension trial designed to evaluate the long-term safety over 12 months of TNX-102 SL tablets taken daily at bedtime for the treatment of fibromyalgia.
- Trial name
- BESTFIT-OLE (NCT02015234)
- Testing
- TNX-102 SL
- Where
- 13 sites in United States
- Volunteers
- 158 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Primary Fibromyalgia
BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)
TNX-102 capsules [formerly known as very low dose (VLD) cyclobenzaprine] at bedtime have shown promise as a treatment of fibromyalgia, but the drug required new formulation technology for bedtime use.
- Trial name
- BESTFIT (NCT01903265)
- Testing
- TNX-102 SL 2.8mg
- Where
- 17 sites in United States
- Volunteers
- 205 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Primary Fibromyalgia
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
This is a Phase 3, open-label, extension trial designed to evaluate the long term safety and efficacy over 3 months of TNX-102 SL tablets taken daily at bedtime for the treatment of Fibromyalgia (FM).
- Trial name
- NCT02589275
- Testing
- TNX-102 SL Tablet 2.8 mg
- Where
- 33 sites in United States
- Volunteers
- 375 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Primary Fibromyalgia
Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia
The purpose of this study is to evaluate the long-term safety and efficacy of milnacipran in pediatric patients aged 13 to 17 years with primary fibromyalgia.
- Trial name
- MyFi (NCT01331109)
- Testing
- Milnacipran
- Where
- 31 sites in United States
- Volunteers
- 57 people
- Sponsor
- Forest Laboratories
Primary Fibromyalgia
Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia
The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacokinetics of milnacipran in pediatric patients aged 13 to 17 years with primary fibromyalgia.
- Trial name
- MyFi (NCT01328002)
- Testing
- Milnacipran
- Where
- 47 sites in United States
- Volunteers
- 116 people
- Sponsor
- Forest Laboratories
Fibromyalgia, Primary, Fibromyalgia, Secondary
A Study for Adult Patients With Fibromyalgia
The main purpose of this study is to determine if 30 milligrams (mg) of duloxetine is effective in the treatment of fibromyalgia compared to placebo.
- Trial name
- HMGG (NCT00965081)
- Testing
- Duloxetine
- Where
- 4 sites in Mexico
- Volunteers
- 308 people
- Sponsor
- Eli Lilly and Company
Fibromyalgia
A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome
The purpose of this study is to determine whether duloxetine is safe and effective in the treatment of adolescents with Juvenile Primary Fibromyalgia Syndrome (JPFS). This trial consists of two distinct study periods.
- Trial name
- NCT01237587
- Testing
- Duloxetine
- Where
- 33 sites in United States, Argentina and 2 more
- Volunteers
- 184 people
- Sponsor
- Eli Lilly and Company